AN OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF THE FIRST LINE NIVOLUMAB PLUS IPILIMUMAB WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED / RECURRENT NON-SMALL CELL LUNG CANCER IN JAPAN (LIGHT-NING)
Latest Information Update: 24 Sep 2026
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LIGHT-NING
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 02 Jun 2026 Planned End Date changed from 1 Jun 2026 to 31 Mar 2027.
- 02 Jun 2026 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.
- 08 Jul 2025 Planned End Date changed from 30 Apr 2023 to 1 Jun 2026.